HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Pyoderma — Clinical Guidelines

Overview

Pyoderma gangrenosum (PG) is an uncommon, neutrophilic, ulcerative skin disorder often characterized by painful skin lesions that can mimic other conditions such as venous ulcers or infections. It can occur in various clinical settings, including post-surgical wounds, chronic inflammatory diseases, and as a complication of certain therapies 1 7 15.

Diagnosis

Clinical Features: Rapidly enlarging ulcers, painful nature, and lack of history of trauma 19.

Histopathological Criteria: Epidermotropism of inflammatory cells differentiates PG from venous leg ulcers 6.

Diagnostic Tools: Biopsy of ulcer margins showing specific histopathological features 6.

Diagnostic Scoring Systems: The PARACELSUS score can aid in diagnosing PG 9.

Differential Diagnosis: Important to rule out venous ulcers, infections, and other inflammatory conditions 19.

Management

First-Line Treatment: Prednisolone remains the primary initial therapy 2.

Adjunctive Therapies: Ciclosporin has shown efficacy compared to prednisolone 13 (Evidence: Moderate).

Other Treatments: Topical therapy, dapsone, and other immunosuppressants may be used 11.

Biologic Agents: Increasing use but limited evidence; access varies by healthcare system 2.

Steroid Therapy Considerations: Use cautiously in post-surgical settings due to potential immunosuppression 7.

Specific Cases: Rituximab use may be associated with PG as an adverse event 8 (Evidence: Weak).

Special Populations

Pediatrics: Rare but associated with underlying systemic diseases; data limited 10.

Comorbidities: PG can complicate conditions like PAPA syndrome and post-surgical states 3 7.

Elderly: Increased susceptibility to misdiagnosis due to overlapping symptoms with chronic conditions 18.

Key Recommendations

Initial Treatment with Prednisolone: First-line therapy for managing pyoderma gangrenosum 2 (Evidence: Moderate).

Consider Ciclosporin for Inadequate Response: Ciclosporin may be superior to prednisolone in refractory cases 13 (Evidence: Moderate).

Biopsy for Confirmation: Histopathological examination is crucial for definitive diagnosis 6 (Evidence: Moderate).

Monitor for Adverse Drug Reactions: Particularly with biologic agents like Rituximab 8 (Evidence: Weak).

Evaluate for Underlying Conditions: Especially in pediatric and atypical presentations 10 3 (Evidence: Moderate).

Use Diagnostic Scoring Systems: Implement tools like PARACELSUS for improved diagnostic accuracy 9 (Evidence: Moderate).

References

1 Parajuli N, Buda C, Tiwari S. Teledermatology- A Life-Saving Experience and its Usefulness in Nepal: A Case Report. Journal of Nepal Health Research Council 2025. link 2 Jenkins M, Watson N, McPhee M, Levell NJ, Arden-Jones M, D Ormerod A et al.. Current prescribing for pyoderma gangrenosum in the UK and access to biologic medications: results from a UK Dermatology Clinical Trials Network survey of dermatologists. Clinical and experimental dermatology 2024. link 3 Alhumam A. Rare Case of Pyoderma Gangrenosum in the Setting of PAPA Syndrome in a 12-Year-Old Child. The international journal of lower extremity wounds 2023. link 4 Wong LL, Borda LJ, Liem T, Keller JJ, Ortega-Loayza AG, Jung E. Atypical Pyoderma Gangrenosum in the Setting of Venous and Arterial Insufficiency. The international journal of lower extremity wounds 2023. link 5 Bennie CJM, Daniels JB, Rao S, Rosychuk RAW, Schissler JR. Efficacy of a quaternary ammonium compound in reducing coagulase-positive staphylococcal colony counts in veterinary dermatology exam rooms following two cleaning instruction protocols. Veterinary dermatology 2022. link 6 Ronicke M, Baur A, Kirr M, Erdmann M, Erfurt-Berge C, Ostalecki C. Epidermotropism of inflammatory cells differentiates pyoderma gangrenosum from venous leg ulcers. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2022. link 7 Aliter H, Idris A. Pyoderma gangrenosum after cardiac surgery. Journal of cardiac surgery 2020. link 8 Aggarwal P. Pyoderma gangrenosum adverse event with Rituximab use: A postmarketing pharmacovigilance analysis. Dermatologic therapy 2020. link 9 Jockenhöfer F, Wollina U, Salva KA, Benson S, Dissemond J. The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum. The British journal of dermatology 2019. link 10 Kechichian E, Haber R, Mourad N, El Khoury R, Jabbour S, Tomb R. Pediatric pyoderma gangrenosum: a systematic review and update. International journal of dermatology 2017. link 11 Al Ghazal P, Dissemond J. Therapy of pyoderma gangrenosum in Germany: results of a survey among wound experts. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2015. link 12 DeFilippis EM, Feldman SR, Huang WW. The genetics of pyoderma gangrenosum and implications for treatment: a systematic review. The British journal of dermatology 2015. link 13 Ormerod AD, Thomas KS, Craig FE, Mitchell E, Greenlaw N, Norrie J et al.. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ (Clinical research ed.) 2015. link 14 Starnes TW, Bennin DA, Bing X, Eickhoff JC, Grahf DC, Bellak JM et al.. The F-BAR protein PSTPIP1 controls extracellular matrix degradation and filopodia formation in macrophages. Blood 2014. link 15 De Felice E, Allen B. Pyoderma gangrenosum; a rare complication of sclerotherapy. Phlebology 2009. link 16 Giorgini S, Martinelli C, Massi D, Leoncini G. A case of difficult Pyoderma gangrenosum diagnosis. Case report. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia 2008. link 17 Tinoco MP, Tamler C, Maciel G, Soares D, Avelleira JC, Azulay D. Pyoderma gangrenosum following isotretinoin therapy for acne nodulocystic. International journal of dermatology 2008. link 18 Contreras-Ruiz J, Kresch-Tronik NS, de la Cruz-Garcia MI, Mercado-Ceja S, Lozano-Platonoff A. Delayed diagnosis of pyoderma gangrenosum: a case study. Ostomy/wound management 2008. link 19 Koo K, Brem H, Lebwohl M. Pyoderma gangrenosum versus chronic venous ulceration: comparison of diagnostic features. Journal of cutaneous medicine and surgery 2006. link 20 Gasparini G, Cantù AM, Rigoni C, Toffolo P, Caputo R, Torti A. Unusual features of pyoderma gangrenosum: two atypical cases. Cutis 1993. link

Pyoderma